Deferoxamine + Deferasirox
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Transfusion-dependent Hemachromatosis
Conditions
Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Trial Timeline
Mar 1, 2008 โ Nov 1, 2008
NCT ID
NCT00749515About Deferoxamine + Deferasirox
Deferoxamine + Deferasirox is a approved stage product being developed by Novartis for Transfusion-dependent Hemachromatosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00749515. Target conditions include Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00749515 | Approved | Completed |
Competing Products
8 competing products in Transfusion-dependent Hemachromatosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 52 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox granule formulation + Deferasirox DT formulation | Novartis | Phase 2 | 52 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 25 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 25 |